Clinical Approach to Lymphadenopathy
Comprehensive Practical Framework1. Symptom Overview
Understanding the clinical significance and classification of lymphadenopathy
Lymphadenopathy is one of the most common clinical findings encountered in primary care and specialty practice. Palpable lymph nodes are detected in approximately 50% of healthy adults, though most represent benign reactive processes. In primary care settings, unexplained lymphadenopathy accounts for approximately 0.6% of all patient visits, with only 1.1% of these cases ultimately diagnosed as malignancy. However, this percentage rises dramatically with age—in patients over 40 years presenting with unexplained lymphadenopathy, the risk of malignancy increases to approximately 4%, and in patients over 50 with persistent nodes, this risk exceeds 10%.
Definition
Lymphadenopathy refers to lymph nodes that are abnormal in size, consistency, or number. A lymph node is generally considered enlarged when it exceeds 1 centimeter in diameter, though this threshold varies by anatomical location. The normal adult body contains approximately 600 lymph nodes, with the majority located in the head, neck, axillae, and inguinal regions where they serve as critical immunological surveillance stations filtering lymphatic fluid for pathogens and abnormal cells.
Classification by Duration
| Category | Duration | Common Causes | Clinical Significance |
|---|---|---|---|
| Acute | Less than 2 weeks | Viral upper respiratory infections, bacterial lymphadenitis, infectious mononucleosis | Usually self-limited; most resolve without intervention; observe for progression |
| Subacute | 2 to 6 weeks | Toxoplasmosis, cat-scratch disease, atypical mycobacteria, early HIV infection | Requires clinical reassessment; consider serologic testing if not resolving |
| Chronic | Greater than 6 weeks | Lymphoma, metastatic carcinoma, tuberculosis, sarcoidosis, autoimmune disease | Higher probability of serious pathology; biopsy often indicated |
Classification by Distribution
Localized Lymphadenopathy
Definition: Enlargement confined to one anatomical region
Frequency: Approximately 75% of all lymphadenopathy cases
Approach: Focus on drainage territory of the affected nodes to identify local infection, inflammation, or malignancy. The most common sites are cervical (55%), inguinal (14%), and axillary (5%).
Generalized Lymphadenopathy
Definition: Enlargement in two or more non-contiguous lymph node regions
Frequency: Approximately 25% of lymphadenopathy cases
Approach: Consider systemic processes including viral infections (Epstein-Barr virus, cytomegalovirus, HIV), autoimmune disorders (systemic lupus erythematosus, rheumatoid arthritis), and hematologic malignancies.
Classification by Physical Characteristics
| Characteristic | Benign Features | Concerning Features |
|---|---|---|
| Size | Less than 1 cm (less than 1.5 cm for inguinal nodes) | Greater than 2 cm; supraclavicular nodes of any size |
| Consistency | Soft, rubbery | Hard, rock-like (suggests carcinoma); firm, rubbery (suggests lymphoma) |
| Tenderness | Tender (suggests acute infection or inflammation) | Non-tender (more concerning for malignancy) |
| Mobility | Mobile, discrete | Fixed to underlying structures or matted together |
| Overlying Skin | Normal | Erythematous and warm (abscess); violaceous (lymphoma); ulcerated (carcinoma) |
Size Thresholds by Location
| Anatomical Location | Upper Limit of Normal | Clinical Notes |
|---|---|---|
| Cervical | 1.0 cm | Most commonly affected region; jugulodigastric node up to 1.5 cm may be normal |
| Axillary | 1.0 cm | Consider breast pathology; epitrochlear nodes greater than 0.5 cm always abnormal |
| Inguinal | 1.5 cm | Commonly palpable in healthy adults due to chronic lower extremity microtrauma |
| Supraclavicular | Any palpable node is abnormal | High malignancy risk (approximately 90% in patients over 40); requires immediate investigation |
| Epitrochlear | 0.5 cm | Consider sarcoidosis, secondary syphilis, lymphoma, or hand infection |
Key Concept: The “SNAP” Features of Concerning Lymphadenopathy
- Supraclavicular location — highest risk for malignancy regardless of other features
- Non-tender and firm — classic features of malignant nodes
- Age over 40 years — malignancy risk increases significantly with age
- Persistent beyond 4-6 weeks — duration is a critical factor in risk stratification
2. Pathophysiology and Mechanisms
Understanding the underlying mechanisms of lymphadenopathy
Understanding why lymph nodes enlarge requires knowledge of their normal structure and function. Lymph nodes are encapsulated organs strategically positioned along lymphatic channels to filter lymph fluid and mount immune responses. Each node contains distinct anatomical zones: the cortex (containing B-cell follicles), paracortex (T-cell zone), and medulla (containing plasma cells and macrophages). Lymph enters through multiple afferent lymphatic vessels, percolates through the node, and exits via a single efferent vessel at the hilum. This architecture allows lymph nodes to serve as immunological checkpoints, sampling antigens and initiating adaptive immune responses.
Lymph Node Structure and Function
| Component | Location | Function | Clinical Relevance |
|---|---|---|---|
| Capsule | Outer layer | Structural support; contains trabeculae | Capsular distension causes tenderness in acute inflammation |
| Cortex (B-cell zone) | Outer region | Contains primary and secondary follicles; antibody production | Follicular hyperplasia in infections; follicular lymphoma arises here |
| Paracortex (T-cell zone) | Between cortex and medulla | T-cell activation and proliferation; antigen presentation | Expands dramatically in viral infections; paracortical hyperplasia |
| Medulla | Central region | Plasma cells produce antibodies; macrophages clear debris | Sinus histiocytosis indicates drainage of inflammatory material |
| High Endothelial Venules | Paracortex | Allow lymphocyte entry from blood | Increased lymphocyte trafficking during immune responses |
Mechanisms of Lymph Node Enlargement
Reactive Hyperplasia
Mechanism: Proliferation of lymphocytes and macrophages in response to antigenic stimulation
Pattern: Follicular (B-cell), paracortical (T-cell), or mixed
Clinical features: Usually tender, mobile, and associated with identifiable infection or inflammation
Infiltration by Inflammatory Cells
Mechanism: Accumulation of neutrophils (suppurative), granulomas (granulomatous), or histiocytes
Pattern: May destroy normal architecture; granulomas have specific morphology
Clinical features: Granulomatous nodes may be firm and matted; suppurative nodes are tender and fluctuant
Neoplastic Infiltration
Mechanism: Primary lymphoid malignancy or metastatic carcinoma replacing normal tissue
Pattern: Effacement of normal architecture; tumor cells in subcapsular sinus (metastases) or diffuse (lymphoma)
Clinical features: Hard, non-tender, fixed; may be matted together
Pathophysiological Categories
| Category | Mechanism | Examples | Typical Characteristics |
|---|---|---|---|
| Infectious | Direct invasion by pathogens or immune response to infection in drainage territory | Bacterial lymphadenitis, viral infections (Epstein-Barr virus, cytomegalovirus), tuberculosis, toxoplasmosis | Often tender; acute onset; may have associated systemic symptoms |
| Immune/Inflammatory | Reactive hyperplasia due to autoimmune or inflammatory conditions | Systemic lupus erythematosus, rheumatoid arthritis, sarcoidosis, Kikuchi disease | Often generalized; associated with other systemic features |
| Malignant — Primary | Clonal proliferation of lymphoid cells within the node | Hodgkin lymphoma, non-Hodgkin lymphoma, chronic lymphocytic leukemia | Firm, rubbery, non-tender; may be matted; often supraclavicular or mediastinal |
| Malignant — Metastatic | Spread of carcinoma cells via lymphatic drainage from primary tumor | Head and neck carcinoma, breast cancer, lung cancer, melanoma | Hard, rock-like, fixed; location corresponds to lymphatic drainage of primary site |
| Infiltrative/Storage | Accumulation of abnormal cells or material within nodes | Gaucher disease, Niemann-Pick disease, amyloidosis, histiocytosis | Often generalized; hepatosplenomegaly commonly present |
| Drug-Induced | Hypersensitivity reaction or pseudolymphoma | Phenytoin, carbamazepine, allopurinol, sulfonamides | Generalized; may have associated rash, fever, eosinophilia |
Regional Lymph Node Drainage and Clinical Significance
| Lymph Node Region | Drainage Territory | If Enlarged, Consider |
|---|---|---|
| Submental | Lower lip, floor of mouth, tip of tongue | Dental infections, oral cavity malignancy |
| Submandibular | Cheek, lateral lip, gums, anterior tongue | Dental infections, salivary gland pathology, head and neck carcinoma |
| Anterior Cervical | Pharynx, tonsils, thyroid | Upper respiratory infections, pharyngitis, thyroid carcinoma |
| Posterior Cervical | Scalp, neck, nasopharynx | Infectious mononucleosis, toxoplasmosis, nasopharyngeal carcinoma, lymphoma |
| Supraclavicular (Left — Virchow’s node) | Thoracic duct draining abdomen and thorax | Gastric, pancreatic, renal, testicular, ovarian malignancy |
| Supraclavicular (Right) | Mediastinum, lungs, esophagus | Lung carcinoma, esophageal carcinoma, mediastinal lymphoma |
| Axillary | Upper extremity, breast, chest wall | Hand/arm infections, breast carcinoma, melanoma, cat-scratch disease |
| Epitrochlear | Ulnar aspect of forearm and hand | Hand infections, sarcoidosis, secondary syphilis, lymphoma |
| Inguinal | Lower extremity, external genitalia, perineum, lower abdominal wall | Sexually transmitted infections, lower extremity cellulitis, melanoma, vulvar/penile carcinoma |
Often Overlooked Mechanism: Virchow’s Node and the Thoracic Duct
The left supraclavicular (Virchow’s) node has special clinical significance because it represents the terminal drainage point of the thoracic duct, which collects lymph from the entire abdomen, pelvis, and left thorax. Consequently, a palpable left supraclavicular node may be the first sign of an occult abdominal or pelvic malignancy—particularly gastric, pancreatic, or ovarian cancer. This anatomical relationship explains why abdominal malignancies may present with “distant” cervical lymphadenopathy, and why any palpable supraclavicular node demands thorough investigation regardless of size.
Why Timing Matters: The Biology of Benign vs Malignant Nodes
Benign Reactive Nodes
- Rapid enlargement (days) due to immune cell proliferation
- Capsular distension causes tenderness
- Typically regress within 2-4 weeks as antigen is cleared
- Normal architecture preserved
- Often associated with identifiable trigger
Malignant Nodes
- Gradual enlargement (weeks to months) due to tumor growth
- Non-tender because growth is slow and does not cause acute capsular distension
- Progressive enlargement without regression
- Normal architecture effaced by tumor
- Often no identifiable infectious trigger
3. History Taking
A comprehensive approach to eliciting the lymphadenopathy history
Red Flags — Require Urgent Evaluation
- Supraclavicular lymphadenopathy — High risk of malignancy (approximately 90% in adults over 40)
- Unexplained weight loss greater than 10% — Suggests malignancy or chronic infection
- Drenching night sweats — Classic “B symptom” of lymphoma
- Persistent fever without identifiable source — May indicate lymphoma, tuberculosis, or HIV
- Nodes greater than 2 cm, hard, fixed, or matted — Concerning for malignancy
- Progressive enlargement over weeks — Unlike reactive nodes which stabilize or regress
- Age over 40 with unexplained lymphadenopathy — Malignancy risk significantly increased
- Hepatosplenomegaly with lymphadenopathy — Suggests systemic disease (lymphoma, leukemia, storage disorders)
Systematic History: The “NODES” Approach
Use the mnemonic “NODES” to ensure comprehensive history taking for lymphadenopathy:
- N — Number, site, and noticed when: How many nodes? Where exactly? When did you first notice them? Are they getting bigger, smaller, or staying the same?
- O — Other node regions and organ symptoms: Have you noticed lumps anywhere else? Any abdominal fullness? Chest symptoms? This identifies generalized versus localized disease.
- D — Duration and dynamics: How long have the nodes been present? Have they changed in size? Do they fluctuate? Nodes persisting beyond 4-6 weeks require further investigation.
- E — Exposure and epidemiological risk factors: Recent infections? Animal contacts? Travel history? Sexual history? Occupational exposures? Sick contacts with tuberculosis?
- S — Systemic symptoms and associated features: Fever, night sweats, weight loss, fatigue, pruritus, alcohol-induced pain (suggests Hodgkin lymphoma)? Skin rashes? Joint pains?
Targeted Questions by Suspected Cause
| Suspected Cause | Key Features | Ask This Question |
|---|---|---|
| Infectious mononucleosis (Epstein-Barr virus) | Young adult, sore throat, fatigue, posterior cervical nodes | “Have you had a severe sore throat, extreme fatigue, or been in close contact with someone with mono?” |
| Cat-scratch disease | Axillary or epitrochlear nodes, history of cat exposure | “Have you been scratched or bitten by a cat or kitten in the past few weeks?” |
| Tuberculosis | Chronic cervical nodes, immigrant or exposure history, constitutional symptoms | “Have you traveled to or lived in areas where tuberculosis is common? Any known TB contacts? Chronic cough?” |
| HIV infection | Generalized lymphadenopathy, risk factors, other opportunistic signs | “Have you had unprotected sexual contact, shared needles, or had a blood transfusion? When was your last HIV test?” |
| Toxoplasmosis | Posterior cervical nodes, cat exposure, often asymptomatic | “Do you have cats? Have you cleaned a litter box recently or eaten undercooked meat?” |
| Lymphoma | Painless progressive nodes, B symptoms, rubbery consistency | “Have you had unexplained fevers, drenching night sweats, or lost weight without trying? Does the lump hurt after drinking alcohol?” |
| Metastatic carcinoma | Hard fixed node, drainage territory suggests primary site | “Have you noticed any lumps in your breast, skin changes, difficulty swallowing, hoarseness, blood in urine or stool, or abnormal bleeding?” |
| Autoimmune disease (systemic lupus erythematosus) | Generalized nodes, young female, multisystem symptoms | “Do you have joint pain, skin rashes especially on your face, mouth sores, or sensitivity to sunlight?” |
| Sarcoidosis | Bilateral hilar adenopathy, epitrochlear nodes, erythema nodosum | “Have you had any skin nodules, eye problems, shortness of breath, or painful red bumps on your shins?” |
| Sexually transmitted infections | Inguinal lymphadenopathy, genital symptoms | “Have you noticed any genital sores, discharge, or pain? Any new sexual partners?” |
Medication and Social History
Medications That Cause Lymphadenopathy
- Phenytoin — Can cause pseudolymphoma syndrome with generalized lymphadenopathy, fever, rash; may mimic lymphoma histologically
- Carbamazepine — Similar hypersensitivity reaction to phenytoin; part of anticonvulsant hypersensitivity syndrome
- Allopurinol — Hypersensitivity syndrome with lymphadenopathy, rash, eosinophilia (DRESS syndrome)
- Sulfonamides — Can trigger serum sickness-like reaction with lymphadenopathy
- Atenolol and other beta-blockers — Rare cause of drug-induced lupus with lymphadenopathy
- Hydralazine — Drug-induced lupus with generalized lymphadenopathy
- Primidone — Anticonvulsant hypersensitivity syndrome
Social and Occupational History
- Animal contacts: Cats (cat-scratch disease, toxoplasmosis); farm animals (brucellosis); ticks (Lyme disease, tularemia)
- Travel history: Endemic areas for tuberculosis, histoplasmosis, coccidioidomycosis; tropical infections
- Sexual history: HIV risk, syphilis, herpes simplex virus, lymphogranuloma venereum (inguinal nodes)
- Occupation: Healthcare workers (tuberculosis exposure); hunters and butchers (tularemia); gardeners (sporotrichosis)
- Intravenous drug use: HIV risk, bacterial endocarditis with septic emboli
- Diet: Raw or undercooked meat (toxoplasmosis); unpasteurized dairy (brucellosis)
- Tobacco use: Risk factor for head and neck carcinoma, lung cancer with mediastinal or supraclavicular nodes
Constitutional Symptoms: The “B Symptoms” of Lymphoma
Recognizing B Symptoms
The presence of B symptoms in a patient with lymphadenopathy significantly increases the probability of lymphoma and indicates more advanced disease with worse prognosis. Always ask specifically about:
- Fever: Unexplained fever greater than 38°C (100.4°F) — distinguish from infectious causes
- Night sweats: Drenching sweats requiring change of bedclothes — not just “feeling warm at night”
- Weight loss: Unintentional loss of greater than 10% body weight in 6 months
Additionally, ask about pruritus (generalized itching without rash) and alcohol-induced lymph node pain — both are associated with Hodgkin lymphoma, though not part of the formal B symptom definition.
Timeline Questions: Critical for Risk Stratification
| Question | Why It Matters | Clinical Implication |
|---|---|---|
| “When did you first notice the lump?” | Duration is a key predictor of etiology | Nodes present greater than 4-6 weeks need investigation; nodes greater than 12 weeks have higher malignancy risk |
| “Is it getting bigger, smaller, or staying the same?” | Trajectory distinguishes reactive from neoplastic | Progressive enlargement is concerning; shrinking nodes are reassuring |
| “Does the size fluctuate?” | Fluctuating size suggests reactive process | Malignant nodes do not typically wax and wane |
| “Have you had this before?” | Recurrent nodes may indicate chronic infection or relapsing disease | Consider recurrent infections, autoimmune disease, or recurrent malignancy |
| “Were you sick before the lump appeared?” | Identifies potential infectious trigger | Reactive nodes often follow viral illness by 1-2 weeks |
4. Physical Examination
A systematic head-to-toe approach for lymphadenopathy
Systematic Framework: Use the “Complete Lymphatic Survey” approach — examine ALL lymph node regions systematically, even when the patient presents with a single palpable node. Document the location, size, number, consistency, tenderness, mobility, and overlying skin changes for each node group.
General Inspection
- Appearance: Does the patient look well or unwell? Cachexia suggests malignancy or chronic infection. Pallor may indicate anemia from marrow infiltration or chronic disease.
- Visible masses: Obvious cervical or supraclavicular swelling may be visible before palpation. Large axillary nodes may cause arm asymmetry.
- Skin changes: Jaundice (hepatic involvement), rash (viral exanthem, drug reaction, dermatomyositis), erythema nodosum (sarcoidosis), Kaposi sarcoma lesions (HIV/AIDS).
- Respiratory effort: Tachypnea or stridor may indicate mediastinal lymphadenopathy causing airway compression.
- Scratch marks: Generalized excoriations without primary rash may indicate pruritus of lymphoma.
Vital Signs
| Vital Sign | What to Look For | Clinical Significance |
|---|---|---|
| Temperature | Fever (greater than 38°C); pattern of fever | Pel-Ebstein fever (cyclical) classic for Hodgkin lymphoma; persistent low-grade fever in infections; high spiking fevers in bacterial lymphadenitis |
| Heart Rate | Tachycardia | May indicate infection, anemia, or hyperthyroidism; relative bradycardia with fever suggests typhoid or intracellular infections |
| Blood Pressure | Hypotension | Sepsis from bacterial lymphadenitis; adrenal involvement in disseminated histoplasmosis or tuberculosis |
| Respiratory Rate | Tachypnea | Mediastinal mass with airway compression; pleural effusion; pulmonary involvement of lymphoma or sarcoidosis |
| Weight | Document and compare to prior weights | Unintentional weight loss greater than 10% is a B symptom; important for staging and prognosis |
Lymph Node Examination: Systematic Approach
Head and Neck Nodes
| Region | Technique | Associated Pathology |
|---|---|---|
| Pre-auricular | Palpate anterior to tragus | Conjunctival or eyelid infections; oculoglandular tularemia; viral conjunctivitis |
| Post-auricular | Palpate over mastoid process | Scalp infections; rubella (classic finding); otitis externa |
| Occipital | Palpate at base of skull posteriorly | Scalp infections; pediculosis; rubella; secondary syphilis |
| Submental | Palpate under chin with head slightly flexed | Lower lip, floor of mouth, tongue tip infections; oral cavity carcinoma |
| Submandibular | Palpate under mandible; distinguish from salivary gland | Dental infections; oral cavity pathology; distinguish from submandibular gland enlargement |
| Anterior cervical (deep chain) | Palpate along anterior border of sternocleidomastoid | Upper respiratory infections; pharyngitis; thyroid carcinoma (Delphian node) |
| Posterior cervical | Palpate posterior to sternocleidomastoid | Infectious mononucleosis (classic); toxoplasmosis; tuberculosis; nasopharyngeal carcinoma |
| Supraclavicular | Palpate in supraclavicular fossa; have patient perform Valsalva maneuver to make nodes more prominent | HIGH MALIGNANCY RISK — Left (Virchow’s node): abdominal malignancy; Right: thoracic malignancy |
Axillary Nodes
- Technique: Support the patient’s arm and palpate high into the axilla along the chest wall. Examine central, lateral, pectoral, and subscapular node groups.
- Findings to note: Size, number, consistency, tenderness, fixation to chest wall or skin.
- Clinical significance: Breast pathology (carcinoma, infection); upper extremity infections; cat-scratch disease; melanoma of the arm or trunk.
Epitrochlear Nodes
- Technique: Palpate proximal and anterior to the medial epicondyle while supporting the slightly flexed elbow.
- Normal: Generally not palpable; any node greater than 0.5 cm is abnormal.
- Clinical significance: Sarcoidosis, secondary syphilis, HIV infection, lymphoma, chronic hand infections, tularemia.
Inguinal Nodes
- Technique: Palpate along the inguinal ligament (horizontal group) and along the saphenous vein (vertical group).
- Normal: Small (less than 1.5 cm), soft, mobile nodes are often palpable in healthy adults.
- Clinical significance: Sexually transmitted infections; lower extremity cellulitis; perineal or genital malignancy; melanoma of lower extremity.
Popliteal Nodes
- Technique: Palpate deep in the popliteal fossa with knee slightly flexed.
- Normal: Not palpable in healthy adults.
- Clinical significance: Foot or lower leg infections; melanoma of heel or posterior calf.
Characterizing Lymph Nodes: The 6-Point Assessment
| Characteristic | How to Assess | Benign Suggestion | Malignant Suggestion |
|---|---|---|---|
| Size | Measure in centimeters; use two dimensions | Less than 1 cm (less than 1.5 cm inguinal) | Greater than 2 cm; any supraclavicular node |
| Consistency | Soft, firm, rubbery, or hard | Soft or slightly firm | Rock-hard (carcinoma); firm-rubbery (lymphoma) |
| Tenderness | Palpate and ask about pain | Tender (acute infection/inflammation) | Non-tender (typical of malignancy) |
| Mobility | Attempt to move node over underlying structures | Mobile, discrete | Fixed to underlying tissue or skin |
| Matting | Assess if nodes are separate or fused together | Discrete, separate nodes | Matted together (tuberculosis, lymphoma, metastatic carcinoma) |
| Overlying skin | Inspect for erythema, warmth, sinus formation | Normal skin; erythema suggests infection | Ulceration (carcinoma); violaceous hue (lymphoma); sinus tract (tuberculosis, actinomycosis) |
Associated Physical Examination Findings
Oropharyngeal Examination
- Tonsillar enlargement and exudate: Infectious mononucleosis, streptococcal pharyngitis
- Palatal petechiae: Infectious mononucleosis
- Oral ulcers: Systemic lupus erythematosus, HIV, Behçet disease
- White patches: Oral candidiasis (immunocompromised), leukoplakia (malignancy risk)
- Gingival hypertrophy: Acute myeloid leukemia
Skin Examination
- Maculopapular rash: Viral exanthem, drug reaction, secondary syphilis, acute HIV
- Erythema nodosum: Sarcoidosis, tuberculosis, inflammatory bowel disease, streptococcal infection
- Skin nodules or tumors: Metastatic carcinoma, cutaneous lymphoma, Kaposi sarcoma
- Scratch marks in drainage territory: Local infection source
- Cat scratches: Cat-scratch disease (check hands and arms)
Abdominal Examination
- Hepatomegaly: Lymphoma, leukemia, infectious mononucleosis, metastatic disease
- Splenomegaly: Infectious mononucleosis, lymphoma, leukemia, portal hypertension
- Hepatosplenomegaly with lymphadenopathy: Strongly suggests systemic disease (lymphoproliferative disorder, storage disease)
- Abdominal masses: Lymphoma, metastatic carcinoma
Expected Findings by Etiology
| Condition | Node Characteristics | Distribution | Associated Findings |
|---|---|---|---|
| Viral upper respiratory infection | Small, soft, tender, mobile | Anterior cervical | Rhinorrhea, pharyngitis, low-grade fever |
| Infectious mononucleosis | Moderate size, firm, tender | Posterior cervical (classic), generalized | Tonsillar enlargement, palatal petechiae, splenomegaly, fatigue |
| Cat-scratch disease | Large (2-5 cm), tender, may suppurate | Regional (axillary or epitrochlear for arm scratch) | Papule at inoculation site, low-grade fever |
| Tuberculosis | Firm, matted, non-tender, may have sinus | Cervical (scrofula), often unilateral | Night sweats, weight loss, cough; may have pulmonary findings |
| HIV infection | Firm, non-tender, mobile | Generalized; posterior cervical, axillary, epitrochlear | Oral candidiasis, seborrheic dermatitis, hairy leukoplakia |
| Hodgkin lymphoma | Firm, rubbery, non-tender, discrete or matted | Cervical (70%), mediastinal; contiguous spread | B symptoms, pruritus, alcohol-induced pain; splenomegaly |
| Non-Hodgkin lymphoma | Firm, rubbery, non-tender | Often generalized; extranodal sites common | Hepatosplenomegaly, skin involvement, GI symptoms possible |
| Metastatic carcinoma | Hard, rock-like, fixed, non-tender | Regional to primary site | Signs related to primary tumor; weight loss, cachexia |
| Systemic lupus erythematosus | Small to moderate, soft, non-tender | Generalized | Malar rash, oral ulcers, arthritis, serositis |
| Sarcoidosis | Firm, non-tender, discrete | Bilateral hilar (on imaging); epitrochlear | Erythema nodosum, uveitis, skin plaques, bilateral hilar adenopathy on chest radiograph |
Important Teaching Point
Many concerning conditions have subtle or normal examination findings! Early lymphoma may present with a single, small, non-tender node that feels similar to reactive lymphadenopathy. The key differentiator is often the clinical trajectory (progressive versus resolving) rather than physical characteristics alone. Similarly, deep lymphadenopathy (mediastinal, retroperitoneal) may cause systemic symptoms without any palpable peripheral nodes. Always correlate examination findings with history, particularly duration, progression, and constitutional symptoms.
5. Differential Diagnosis
Systematic approach organized by probability and clinical features
Acute Lymphadenopathy (Duration: Less than 2 weeks)
| Probability | Condition | Key Features | Red Flags |
|---|---|---|---|
| COMMON (approximately 70%) | Viral upper respiratory tract infection | Bilateral anterior cervical nodes, rhinorrhea, sore throat, low-grade fever | Usually none; self-limited |
| COMMON | Bacterial pharyngitis (Group A Streptococcus) | Tender anterior cervical nodes, tonsillar exudate, fever, absence of cough | Peritonsillar abscess if unilateral swelling with trismus |
| COMMON | Dental or periodontal infection | Submandibular or submental nodes, dental pain, gingival swelling | Ludwig angina if floor of mouth involvement |
| LESS COMMON (approximately 20%) | Acute bacterial lymphadenitis | Single enlarged tender node, overlying erythema and warmth, fever | Fluctuance suggests abscess formation requiring drainage |
| LESS COMMON | Infectious mononucleosis (Epstein-Barr virus) | Posterior cervical nodes, severe pharyngitis, fatigue, splenomegaly | Splenic rupture risk; airway compromise from tonsillar enlargement |
| LESS COMMON | Acute HIV infection (seroconversion illness) | Generalized lymphadenopathy, fever, rash, pharyngitis, mucosal ulcers | High-risk exposure history; routine HIV testing often negative initially |
| UNCOMMON BUT SERIOUS (approximately 10%) | Kawasaki disease | Cervical node greater than 1.5 cm, fever greater than 5 days, conjunctivitis, rash, extremity changes | Coronary artery aneurysm risk if untreated |
| UNCOMMON BUT SERIOUS | Diphtheria | “Bull neck” appearance, pharyngeal pseudomembrane, cervical lymphadenopathy | Airway obstruction; myocarditis; rare in vaccinated populations |
Subacute Lymphadenopathy (Duration: 2 to 6 weeks)
Clinical Approach to Subacute Lymphadenopathy:
- Step 1: Reassess — Has the node changed since initial presentation? Shrinking nodes are reassuring.
- Step 2: Review exposures — Cat contact, travel, sexual history, tuberculosis contacts, occupational risks.
- Step 3: Consider serologic testing — Epstein-Barr virus, cytomegalovirus, HIV, toxoplasmosis, Bartonella.
- Step 4: If no diagnosis and node persists or enlarges, proceed to biopsy.
| Probability | Condition | Key Features | Expected Course |
|---|---|---|---|
| COMMON | Resolving viral infection | Node gradually shrinking, no new symptoms, improving energy | Complete resolution within 4-6 weeks |
| COMMON | Cat-scratch disease (Bartonella henselae) | Regional nodes (axillary, epitrochlear, cervical), cat exposure, papule at scratch site | Spontaneous resolution in 2-4 months; may suppurate |
| LESS COMMON | Toxoplasmosis | Posterior cervical nodes, often asymptomatic, cat or raw meat exposure | Self-limited in immunocompetent; may persist for months |
| LESS COMMON | Cytomegalovirus infection | Generalized lymphadenopathy, mononucleosis-like but heterophile-negative | Resolution over weeks; may have prolonged fatigue |
| LESS COMMON | Secondary syphilis | Generalized non-tender nodes, epitrochlear involvement, rash on palms and soles | Resolves with treatment; untreated progresses to latent phase |
| UNCOMMON BUT SERIOUS | Kikuchi-Fujimoto disease (histiocytic necrotizing lymphadenitis) | Posterior cervical nodes, young Asian women, fever, leukopenia | Self-limited over 1-4 months; may recur; rule out lupus |
| UNCOMMON BUT SERIOUS | Atypical mycobacterial infection | Cervical nodes in children, violaceous discoloration, minimal tenderness | May require excision; responds poorly to standard tuberculosis therapy |
Chronic Lymphadenopathy (Duration: Greater than 6 weeks)
Step-by-Step Approach to Chronic Lymphadenopathy:
- Step 1: Identify red flags — Supraclavicular location, B symptoms, hard/fixed nodes, age over 40
- Step 2: Consider the “Big Four” causes — Lymphoma, metastatic carcinoma, tuberculosis, HIV infection
- Step 3: Obtain baseline investigations — Complete blood count, lactate dehydrogenase, chest radiograph, HIV test
- Step 4: If diagnosis remains unclear after 4-6 weeks of observation or if concerning features present, proceed to excisional biopsy
| Probability | Condition | Approximate Frequency | Key Distinguishing Features |
|---|---|---|---|
| COMMON | Reactive hyperplasia (non-specific) | 30-40% of biopsied nodes | Diagnosis of exclusion; nodes usually small, stable, no concerning features |
| COMMON | Hodgkin lymphoma | 10-15% of biopsied nodes | Cervical or mediastinal, contiguous spread, B symptoms, bimodal age distribution |
| COMMON | Non-Hodgkin lymphoma | 15-20% of biopsied nodes | Generalized nodes, extranodal involvement, older adults, variable B symptoms |
| LESS COMMON | Metastatic carcinoma | 5-10% of biopsied nodes | Hard, fixed, location suggests primary; older patients; weight loss |
| LESS COMMON | Tuberculosis (scrofula) | 5-10% in endemic areas | Cervical, matted, may have sinus formation, exposure or immigration history |
| LESS COMMON | Sarcoidosis | 5% | Bilateral hilar adenopathy, epitrochlear nodes, erythema nodosum, African American predilection |
| LESS COMMON | Chronic lymphocytic leukemia | 5% | Generalized small nodes, older adults, lymphocytosis on blood count |
| UNCOMMON | Systemic lupus erythematosus | 2-3% | Generalized, young women, multisystem involvement, positive antinuclear antibody |
| UNCOMMON | Castleman disease | Less than 1% | Unicentric (single site) or multicentric; may have systemic symptoms |
| UNCOMMON | Rosai-Dorfman disease (sinus histiocytosis) | Less than 1% | Massive bilateral cervical nodes, fever, elevated erythrocyte sedimentation rate |
Anatomical Approach to Localized Lymphadenopathy
Head and Neck
Upper respiratory tract infections
Dental and periodontal infections
Infectious mononucleosis
Tuberculosis (scrofula)
Head and neck squamous cell carcinoma
Thyroid carcinoma
Nasopharyngeal carcinoma
Lymphoma
Supraclavicular
Left (Virchow’s node):
Gastric carcinoma
Pancreatic carcinoma
Renal cell carcinoma
Ovarian or testicular carcinoma
Right:
Lung carcinoma
Esophageal carcinoma
Mediastinal lymphoma
Axillary
Upper extremity infections
Cat-scratch disease
Breast carcinoma
Melanoma (arm or trunk)
Lymphoma
Silicone breast implant reaction
Hidradenitis suppurativa
Inguinal
Lower extremity cellulitis
Sexually transmitted infections
Genital herpes simplex
Primary syphilis (chancre)
Lymphogranuloma venereum
Melanoma (lower extremity)
Vulvar, penile, or anal carcinoma
Drug-Induced Lymphadenopathy
| Drug or Drug Class | Mechanism | Characteristics | Time to Resolution After Stopping |
|---|---|---|---|
| Phenytoin | Pseudolymphoma syndrome; hypersensitivity reaction | Generalized lymphadenopathy, fever, rash, eosinophilia; may mimic lymphoma on biopsy | Weeks to months; biopsy changes may persist |
| Carbamazepine | Anticonvulsant hypersensitivity syndrome (DRESS) | Generalized nodes, fever, rash, hepatitis, eosinophilia | 2-6 weeks after discontinuation |
| Allopurinol | Drug reaction with eosinophilia and systemic symptoms (DRESS) | Generalized lymphadenopathy, severe rash, organ involvement | Weeks; may have prolonged course |
| Sulfonamides | Serum sickness-like reaction | Lymphadenopathy, fever, rash, arthralgias | 1-2 weeks after stopping |
| Hydralazine | Drug-induced lupus | Generalized nodes, arthralgias, serositis, positive anti-histone antibodies | Weeks to months |
| Atenolol | Drug-induced lupus (rare) | Generalized lymphadenopathy with lupus-like features | Weeks to months |
| Lamotrigine | Hypersensitivity syndrome | Lymphadenopathy with rash (may be severe), fever, hepatitis | 2-4 weeks |
| Minocycline | Drug-induced lupus; hypersensitivity | Lymphadenopathy, arthralgias, positive antinuclear antibody | Weeks to months |
| Isoniazid | Drug-induced lupus | Generalized lymphadenopathy, arthralgias, fever | Weeks after discontinuation |
Quick Reference: “If You See This, Think This”
| Clinical Clue | Think This First | Next Step |
|---|---|---|
| Posterior cervical nodes in young adult with sore throat | Infectious mononucleosis | Heterophile antibody test (Monospot); check for splenomegaly |
| Axillary node with history of cat scratch | Cat-scratch disease | Bartonella serology; look for inoculation papule; observe |
| Left supraclavicular node (Virchow’s node) | Abdominal malignancy (gastric, pancreatic) | Urgent CT chest/abdomen/pelvis; expedited biopsy |
| Right supraclavicular node | Thoracic malignancy (lung, esophageal) | Chest CT; consider bronchoscopy; expedited biopsy |
| Hard, fixed cervical node in smoker over 50 | Metastatic head and neck squamous cell carcinoma | ENT referral; CT neck; panendoscopy with biopsy |
| Generalized lymphadenopathy with splenomegaly | Lymphoproliferative disorder or infectious mononucleosis | Complete blood count with differential; peripheral smear; LDH; EBV serology |
| Epitrochlear node greater than 0.5 cm | Sarcoidosis, syphilis, HIV, lymphoma | HIV test; RPR; chest radiograph; consider biopsy |
| Matted cervical nodes with sinus formation | Tuberculosis (scrofula) | Tuberculin skin test or interferon-gamma release assay; chest radiograph; biopsy with culture |
| Bilateral hilar adenopathy on chest radiograph | Sarcoidosis (if asymptomatic); lymphoma; tuberculosis | CT chest; serum ACE level; bronchoscopy with biopsy if indicated |
| Generalized nodes in patient on phenytoin | Drug-induced pseudolymphoma | Stop phenytoin; observe for resolution; biopsy if not improving |
| Inguinal nodes with genital ulcer | Primary syphilis, herpes simplex, lymphogranuloma venereum | RPR and treponemal test; HSV PCR of ulcer; Chlamydia testing |
| Cervical node with B symptoms in young adult | Hodgkin lymphoma | Excisional biopsy; CT chest/abdomen/pelvis for staging |
6. Diagnostic Investigations
A stepwise, cost-effective approach guided by clinical suspicion
Baseline Investigations for All Patients with Unexplained Lymphadenopathy
| Investigation | Purpose | What to Look For | Practical Points |
|---|---|---|---|
| Complete blood count with differential | Screen for hematologic malignancy and infection | Lymphocytosis (chronic lymphocytic leukemia, viral); atypical lymphocytes (infectious mononucleosis); cytopenias (marrow infiltration); eosinophilia (Hodgkin lymphoma, drug reaction, parasites) | Request peripheral blood smear if abnormalities detected |
| Peripheral blood smear | Morphologic assessment of blood cells | Atypical lymphocytes; smudge cells (chronic lymphocytic leukemia); blast cells; abnormal lymphocyte morphology | Essential if complete blood count is abnormal; can be diagnostic |
| Erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) | Non-specific markers of inflammation | Elevated in infection, autoimmune disease, and malignancy; very high ESR (greater than 100) suggests serious pathology | Non-specific but helps gauge disease activity; useful for monitoring |
| Lactate dehydrogenase (LDH) | Marker of cell turnover; prognostic in lymphoma | Elevated in lymphoma, hemolysis, and other malignancies; correlates with tumor burden | Elevated LDH with lymphadenopathy increases suspicion for lymphoma |
| Liver function tests | Assess hepatic involvement | Elevated transaminases (infectious mononucleosis, lymphoma infiltration); elevated alkaline phosphatase (infiltrative disease) | Abnormalities may suggest systemic disease |
| Renal function tests | Baseline assessment; detect complications | Elevated creatinine may indicate tumor lysis risk or renal involvement | Important before contrast imaging or chemotherapy |
| HIV test (fourth-generation antigen/antibody) | Rule out HIV infection | HIV causes generalized lymphadenopathy; may be the presenting sign | Offer to all patients with unexplained lymphadenopathy; consider acute infection window |
| Chest radiograph | Identify mediastinal lymphadenopathy and pulmonary pathology | Hilar adenopathy (sarcoidosis, lymphoma, tuberculosis); pulmonary masses; pleural effusion | Normal radiograph does not exclude mediastinal disease; CT more sensitive |
Targeted Investigations by Suspected Etiology
If Suspecting Infectious Mononucleosis (Epstein-Barr Virus)
First-Line Tests
- Heterophile antibody test (Monospot): Rapid; sensitivity approximately 85% in adults; may be negative in first week
- Complete blood count: Lymphocytosis with greater than 10% atypical lymphocytes supports diagnosis
Second-Line Tests
- EBV-specific serology (viral capsid antigen IgM and IgG, early antigen, EBNA): If Monospot negative but clinical suspicion high; helps distinguish acute from past infection
- Liver function tests: Transaminitis occurs in approximately 90% of cases
If Suspecting Cat-Scratch Disease (Bartonella henselae)
First-Line Tests
- Bartonella henselae serology (IgM and IgG): IgG titer greater than 1:256 or IgM positive supports diagnosis; sensitivity approximately 90%
- Clinical diagnosis: Often sufficient with clear cat exposure and characteristic presentation
Second-Line Tests
- PCR of aspirated node material: High specificity; useful if serology indeterminate
- Histopathology of excised node: Stellate granulomas with central necrosis; Warthin-Starry stain may show organisms
If Suspecting Tuberculosis
First-Line Tests
- Tuberculin skin test (Mantoux) or Interferon-gamma release assay (QuantiFERON, T-SPOT): Indicates exposure; does not distinguish latent from active disease
- Chest radiograph: Pulmonary tuberculosis present in approximately 50% of tuberculous lymphadenitis
- Fine needle aspiration: Send for acid-fast bacilli smear, culture, and cytology
Second-Line Tests
- Excisional biopsy: Higher diagnostic yield than fine needle aspiration; caseous granulomas characteristic
- Mycobacterial culture: Gold standard but takes 2-8 weeks; enables drug sensitivity testing
- PCR for Mycobacterium tuberculosis: Rapid; useful when smear negative but suspicion high
If Suspecting Lymphoma
First-Line Tests
- Excisional lymph node biopsy: Essential for diagnosis; provides tissue architecture needed for subtyping
- CT chest, abdomen, and pelvis: Staging; identifies additional lymphadenopathy and organ involvement
- LDH: Prognostic marker; elevated in high-grade lymphomas
Second-Line Tests
- PET-CT scan: Staging for Hodgkin lymphoma and aggressive non-Hodgkin lymphoma; identifies metabolically active disease
- Bone marrow biopsy: Staging; detects marrow involvement
- Flow cytometry: Immunophenotyping of lymphocytes; essential for diagnosis and classification
If Suspecting Metastatic Carcinoma
First-Line Tests
- Fine needle aspiration or core biopsy: Confirms malignancy; immunohistochemistry helps identify primary
- CT scan of relevant region: Based on lymph node location (head and neck CT for cervical; chest CT for supraclavicular)
Second-Line Tests
- PET-CT scan: Identify occult primary; staging of known malignancy
- Site-specific investigations: Mammography, upper endoscopy, colonoscopy, bronchoscopy as indicated by clinical and imaging findings
If Suspecting Autoimmune Disease
First-Line Tests
- Antinuclear antibody (ANA): Screening for systemic lupus erythematosus and other connective tissue diseases
- Rheumatoid factor: Elevated in rheumatoid arthritis and other autoimmune conditions
- Complement levels (C3, C4): Low in active systemic lupus erythematosus
Second-Line Tests
- Anti-double-stranded DNA antibodies: Specific for systemic lupus erythematosus
- Extractable nuclear antigens (ENA panel): Anti-Smith, anti-RNP, anti-Ro, anti-La
- Urinalysis: Proteinuria or hematuria suggests lupus nephritis
If Suspecting Sarcoidosis
First-Line Tests
- Chest radiograph: Bilateral hilar adenopathy (stage I); with parenchymal changes (stage II-III)
- Serum angiotensin-converting enzyme (ACE): Elevated in approximately 60%; not specific; useful for monitoring
- Serum calcium: Hypercalcemia occurs in approximately 10-15%
Second-Line Tests
- High-resolution CT chest: Characterizes parenchymal involvement; identifies lymphadenopathy pattern
- Tissue biopsy: Non-caseating granulomas; exclude other granulomatous diseases
- Bronchoscopy with bronchoalveolar lavage and transbronchial biopsy: High yield for pulmonary sarcoidosis
Lymph Node Biopsy: When and How
Indications for Urgent Biopsy
- Supraclavicular lymphadenopathy of any size
- Lymph node greater than 2 cm with no clear infectious cause
- Hard, fixed, or matted nodes
- B symptoms present (fever, night sweats, weight loss)
- Progressive enlargement over 2 or more weeks
- Persistence beyond 4-6 weeks without explanation
- Age over 40 with unexplained lymphadenopathy
| Biopsy Method | Advantages | Limitations | Best Used For |
|---|---|---|---|
| Fine needle aspiration (FNA) | Minimally invasive; rapid; inexpensive; can be done in clinic | Cannot assess architecture; may miss lymphoma; high false-negative rate for Hodgkin lymphoma | Suspected metastatic carcinoma; recurrent known malignancy; initial assessment when infectious cause suspected |
| Core needle biopsy | Provides tissue architecture; less invasive than excision | May still be insufficient for lymphoma subtyping; sampling error | Deep nodes not amenable to excision; suspected lymphoma when excision not feasible |
| Excisional biopsy | Provides complete architecture; gold standard for lymphoma diagnosis; highest diagnostic yield | More invasive; requires surgery; potential complications (bleeding, infection, nerve injury) | Suspected lymphoma; unexplained persistent lymphadenopathy; when FNA non-diagnostic |
| Incisional biopsy | Provides tissue from large masses | May not capture heterogeneous areas; incomplete assessment | Very large nodes where complete excision not feasible |
Key Principle: Excisional Biopsy for Suspected Lymphoma
When lymphoma is suspected, excisional biopsy of the most abnormal accessible lymph node is the investigation of choice. Fine needle aspiration has a sensitivity of only 60-70% for lymphoma and cannot provide the architectural information needed for accurate subtyping. If FNA is performed and shows suspicious or atypical lymphoid cells, proceed to excisional biopsy. Avoid multiple FNA attempts that delay definitive diagnosis.
Imaging Modalities
| Imaging | When to Use | What It Shows | Limitations |
|---|---|---|---|
| Ultrasound | First-line for superficial nodes; guide FNA; assess characteristics | Size, shape, echogenicity, hilar architecture, vascularity; can distinguish reactive from suspicious features | Operator-dependent; cannot assess deep nodes; limited staging role |
| CT with contrast | Staging; assess deep lymphadenopathy; identify primary malignancy | Size and distribution of nodes; organ involvement; vascular invasion | Radiation exposure; cannot reliably distinguish benign from malignant based on size alone |
| PET-CT | Staging lymphoma; identify occult primary in carcinoma; assess treatment response | Metabolically active disease; distinguishes active from fibrotic nodes post-treatment | Expensive; false positives with infection/inflammation; limited availability |
| MRI | Soft tissue detail; assess for extranodal extension; pediatric patients (no radiation) | Superior soft tissue contrast; can detect marrow involvement | Expensive; limited availability; motion artifact; contraindicated with some implants |
When to Observe vs. Investigate Further
Criteria for Observation (Watch and Wait)
Short-term observation (2-4 weeks) is appropriate when ALL of the following criteria are met:
- Node is less than 1.5 cm in size
- Patient is under 40 years of age
- Node is soft, mobile, and tender (suggesting reactive process)
- Clear infectious etiology is present or likely (recent upper respiratory infection)
- No supraclavicular involvement
- No B symptoms (fever, night sweats, weight loss)
- No other concerning features on examination or baseline investigations
Reassess in 2-4 weeks. If node is shrinking, continue observation. If node is stable or enlarging, proceed to further investigation or biopsy.
7. Pattern Recognition and Clinical Decision-Making
Practical algorithms and decision pathways
Step 1: Is This Urgent?
| Clinical Scenario | Urgency Level | Immediate Action |
|---|---|---|
| Supraclavicular lymphadenopathy (any size) | EMERGENT | Urgent CT chest/abdomen/pelvis; expedited biopsy within 1-2 weeks; oncology referral |
| Rapidly enlarging node with airway compromise or stridor | EMERGENT | Secure airway; urgent CT neck/chest; same-day ENT or oncology consultation |
| Hard, fixed node in patient over 40 years | EMERGENT | Urgent imaging and biopsy; assume malignancy until proven otherwise |
| Lymphadenopathy with B symptoms (fever, night sweats, weight loss greater than 10%) | URGENT | Complete blood count, LDH, chest radiograph; expedited biopsy within 2 weeks; hematology referral |
| Generalized lymphadenopathy with hepatosplenomegaly | URGENT | Urgent complete blood count with smear; LDH; consider hematology consultation; may need bone marrow biopsy |
| Lymphadenopathy greater than 2 cm persisting beyond 4 weeks | URGENT | Baseline investigations; consider biopsy if no clear benign etiology identified |
| Tender cervical node with recent upper respiratory infection, patient under 40 | ROUTINE | Clinical observation; reassess in 2-4 weeks; investigate if not improving |
| Small (less than 1 cm), soft, mobile inguinal nodes | ROUTINE | Often normal finding; observe unless other concerning features present |
Step 2: Classify by Duration
Acute (Less than 2 weeks)
Proceed to Algorithm A
Focus on infectious causes; observation usually appropriate if no red flags
Subacute (2 to 6 weeks)
Proceed to Algorithm B
Reassess; consider serologic testing; biopsy if progressive or not resolving
Chronic (Greater than 6 weeks)
Proceed to Algorithm C
Higher malignancy risk; biopsy strongly considered; complete staging workup
Step 3: Follow the Appropriate Algorithm
Algorithm A: Acute Lymphadenopathy (Less than 2 weeks)
| Clinical Scenario | Most Likely Diagnosis | Action |
|---|---|---|
| Anterior cervical nodes with sore throat, rhinorrhea, low-grade fever | Viral upper respiratory tract infection | Supportive care; reassess if not improving in 2 weeks |
| Anterior cervical nodes with tonsillar exudate, high fever, no cough | Streptococcal pharyngitis | Rapid strep test or throat culture; treat with antibiotics if positive |
| Posterior cervical nodes with severe fatigue, pharyngitis in young adult | Infectious mononucleosis | Heterophile antibody test; complete blood count; check for splenomegaly; activity restrictions |
| Single tender erythematous node with fluctuance | Bacterial lymphadenitis with abscess | Incision and drainage; antibiotics; consider Staphylococcus coverage |
| Submandibular node with dental pain or gingival swelling | Odontogenic infection | Dental referral; antibiotics; drainage if abscess present |
| Generalized lymphadenopathy with fever, rash, pharyngitis, and high-risk exposure | Acute HIV seroconversion | Fourth-generation HIV test; HIV viral load if high suspicion; repeat testing in 2-4 weeks if initially negative |
Algorithm B: Subacute Lymphadenopathy (2 to 6 weeks)
| Clinical Scenario | Most Likely Diagnosis | Action |
|---|---|---|
| Node shrinking compared to initial presentation | Resolving reactive lymphadenopathy | Continue observation; no further workup if completely resolved by 6 weeks |
| Axillary or epitrochlear node with cat exposure history | Cat-scratch disease | Bartonella serology; supportive care; antibiotics for severe disease or immunocompromised |
| Posterior cervical nodes with mild symptoms, cat or raw meat exposure | Toxoplasmosis | Toxoplasma IgM and IgG serology; usually self-limited; treatment only if severe or immunocompromised |
| Generalized nodes, mononucleosis-like syndrome, heterophile negative | Cytomegalovirus infection | CMV IgM and IgG serology; CMV PCR if immunocompromised; supportive care |
| Node stable or enlarging, no clear etiology after 4 weeks | Unknown — requires tissue diagnosis | Proceed to baseline investigations and consider biopsy |
Algorithm C: Chronic Lymphadenopathy (Greater than 6 weeks)
| Clinical Scenario | Most Likely Diagnosis | Action |
|---|---|---|
| Cervical node with B symptoms, young adult | Hodgkin lymphoma | Excisional biopsy; CT staging; hematology/oncology referral |
| Generalized nodes with hepatosplenomegaly, older adult | Non-Hodgkin lymphoma or chronic lymphocytic leukemia | Complete blood count with smear; flow cytometry; excisional biopsy; bone marrow if indicated |
| Hard fixed cervical node in smoker over 50 | Metastatic squamous cell carcinoma (head and neck primary) | CT neck with contrast; ENT referral; panendoscopy; FNA or biopsy |
| Left supraclavicular node with abdominal symptoms or weight loss | Metastatic abdominal malignancy (gastric, pancreatic) | CT abdomen/pelvis; upper endoscopy; urgent oncology referral |
| Matted cervical nodes with sinus formation, tuberculosis exposure history | Tuberculous lymphadenitis (scrofula) | Tuberculin skin test or interferon-gamma release assay; chest radiograph; excisional biopsy with cultures |
| Bilateral hilar adenopathy with erythema nodosum | Sarcoidosis (Löfgren syndrome) | Serum ACE level; high-resolution CT chest; bronchoscopy if diagnosis unclear |
| Generalized nodes in young woman with rash and joint pain | Systemic lupus erythematosus | Antinuclear antibody; anti-double-stranded DNA; complement levels; urinalysis |
“What Do I Do If…” Decision Reference
| Clinical Situation | Immediate Action | Next Step |
|---|---|---|
| Fine needle aspiration shows “atypical lymphoid cells” | Do NOT reassure patient — this requires further investigation | Proceed to excisional biopsy; FNA cannot reliably exclude lymphoma |
| Fine needle aspiration shows “reactive hyperplasia” but clinical suspicion remains high | Consider sampling error or inadequate specimen | Excisional biopsy if node greater than 2 cm, supraclavicular, or progressive |
| Patient on phenytoin with generalized lymphadenopathy | Stop phenytoin; switch to alternative anticonvulsant | Observe for resolution over 2-4 weeks; biopsy if not improving to exclude true lymphoma |
| Lymph node biopsy shows granulomas | Send tissue for acid-fast bacilli and fungal cultures if not already done | Consider tuberculosis, sarcoidosis, fungal infection, cat-scratch disease; clinical correlation essential |
| Multiple enlarged nodes but patient declines biopsy | Document risks clearly; arrange close follow-up | Repeat clinical assessment in 2-4 weeks; reinforce need for biopsy if progression |
| Lymphadenopathy in patient with known HIV | Check CD4 count and viral load; assess for opportunistic infections | Lower threshold for biopsy — consider lymphoma, mycobacterial infection, Kaposi sarcoma |
| Isolated axillary node in woman with normal breast examination | Arrange mammography (and ultrasound if under 40) | If breast imaging negative, consider other causes (cat-scratch, melanoma); biopsy if persistent |
| Pediatric patient with cervical lymphadenopathy | Viral infections most common; consider atypical mycobacteria | Observe if acute and typical; lower biopsy threshold if violaceous skin or sinus formation (atypical mycobacteria) |
| Biopsy shows metastatic carcinoma but primary unknown | Review immunohistochemistry to guide primary site search | PET-CT scan; site-directed investigations based on immunohistochemistry; oncology referral |
| Patient has lymphadenopathy post-COVID-19 vaccination | Ipsilateral axillary or supraclavicular nodes within 6 weeks of vaccination | Usually reactive — can observe for 4-6 weeks; biopsy if persistent beyond 6 weeks or other concerning features |
Choosing Which Node to Biopsy
Principles for Selecting Biopsy Target:
- Select the most abnormal node — Largest, firmest, or most recently enlarged
- Prioritize by location: Supraclavicular greater than cervical greater than axillary greater than inguinal (inguinal nodes often show non-specific reactive changes)
- Avoid inguinal nodes if possible — High rate of non-diagnostic reactive changes due to chronic lower extremity antigenic stimulation
- Consider accessibility — Superficial nodes preferred over deep nodes when equally suspicious
- Excision over FNA when lymphoma suspected — Architecture essential for diagnosis
Troubleshooting Unexplained Persistent Lymphadenopathy
When Initial Workup Is Negative, Ask These Questions
- Was the biopsy adequate? Was it excisional? Was sufficient tissue sent for flow cytometry, cultures, and special stains?
- Were all specimens processed correctly? Fresh tissue for flow cytometry; tissue in saline for cultures; formalin only for histology
- Should the biopsy be repeated? Consider repeat biopsy of different node if clinical suspicion persists despite “reactive” result
- Have all infectious causes been excluded? Tuberculosis, atypical mycobacteria, fungal infections, Bartonella, toxoplasmosis
- Have autoimmune conditions been considered? Systemic lupus erythematosus, rheumatoid arthritis, Kikuchi disease
- Could this be drug-induced? Review all medications, including those started months ago
- Is specialist review needed? Hematology, infectious disease, or rheumatology input may be valuable
8. Clinical Pearls and Pitfalls
Practical wisdom — learn from successes and avoid common mistakes
Must-Know Clinical Pearls
Critical Pitfalls to Avoid
Key Takeaways
- Lymphadenopathy is common and usually benign, but the clinician’s role is to identify the minority with serious underlying pathology requiring prompt diagnosis and treatment.
- Location is critical: supraclavicular nodes are high-risk regardless of size or other characteristics; epitrochlear nodes greater than 0.5 cm are always abnormal; inguinal nodes are often normally palpable.
- Duration guides management: acute lymphadenopathy (less than 2 weeks) can often be observed; subacute nodes (2-6 weeks) require reassessment; chronic nodes (greater than 6 weeks) need investigation.
- The “SNAP” features identify high-risk patients: Supraclavicular location, Non-tender and firm, Age over 40, Persistent beyond 4-6 weeks.
- Generalized lymphadenopathy (2 or more non-contiguous regions) suggests systemic disease and changes the differential to include viral infections (HIV, Epstein-Barr virus, cytomegalovirus), autoimmune conditions, and hematologic malignancies.
- B symptoms (fever, drenching night sweats, weight loss greater than 10%) significantly increase the probability of lymphoma and should prompt urgent investigation.
- Excisional biopsy is the gold standard for suspected lymphoma because tissue architecture is essential for accurate diagnosis and subtyping. FNA is inadequate for this purpose.
- Always examine all lymph node regions systematically and check for hepatosplenomegaly — these findings fundamentally change the differential diagnosis.
- Review medications in every patient with unexplained lymphadenopathy — drug-induced pseudolymphoma can closely mimic malignancy.
- When in doubt, biopsy — the consequences of missing a malignancy far outweigh the morbidity of a diagnostic lymph node excision.
Quick Reference Algorithm
Systematic Approach to Lymphadenopathy:
- Identify red flags: Supraclavicular location, hard/fixed nodes, B symptoms, age over 40, persistence beyond 4-6 weeks → Urgent investigation and biopsy
- Determine distribution: Localized versus generalized → Different differential diagnoses and workup strategies
- Classify by duration: Acute (less than 2 weeks), subacute (2-6 weeks), or chronic (greater than 6 weeks) → Guides observation versus investigation
- Consider the drainage territory: For localized lymphadenopathy, examine the region drained by the involved nodes for primary pathology
- Obtain baseline investigations: Complete blood count, LDH, HIV test, chest radiograph for unexplained lymphadenopathy
- Pursue targeted testing: Based on clinical suspicion (serology for infectious causes, autoantibodies for autoimmune diseases)
- Decide on biopsy: Excisional biopsy for suspected lymphoma; FNA acceptable for suspected metastatic carcinoma
- Arrange appropriate follow-up: If observing, reassess in 2-4 weeks; ensure patients understand when to return sooner